Annual report [Section 13 and 15(d), not S-K Item 405]

Note 12 - Contingent Liabilities (Details Textual)

v3.25.3
Note 12 - Contingent Liabilities (Details Textual) - USD ($)
12 Months Ended
Oct. 01, 2025
Feb. 29, 2024
Sep. 30, 2025
Sep. 30, 2024
Research and Development Expense     $ 15,588,185 $ 12,782,167
Accounts Payable, Current     3,121,448 2,259,668
Other Liabilities, Noncurrent     1,359,871 4,461,920
Subsequent Event [Member] | Undisclosed Third Party [Member]        
Repayments of Trade Payables $ 1,600,000      
Damages from Product Defects [Member]        
Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate     10,000,000  
Loss Contingency, Commercial Dispute [Member]        
Research and Development Expense       600,000
Loss Contingency, Commercial Dispute [Member] | Research and Development Liability [Member]        
Accounts Payable, Current     2,600,000 900,000
Other Liabilities, Noncurrent     $ 1,400,000 $ 4,500,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member]        
Loss Contingency, Damages Sought, Value   $ 10,000,000    
Loss Contingency Accrual, Product Liability, Net   8,300,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Due Upon Execution of Agreement [Member]        
Loss Contingency Accrual, Product Liability, Net   2,300,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments,One [Member]        
Loss Contingency Accrual, Product Liability, Net   $ 3,500,000    
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)   48 months    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Balance by December 31, 2025 [Member]        
Loss Contingency Accrual, Product Liability, Net   $ 2,500,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments, Two [Member]        
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)   24 months